2024-05-21 13:15:19 ET
Summary
- Dyne Therapeutics stock rallied 27% after reporting positive results from the DELIVER and ACHIEVE trials.
- DYNE-101 showed dose-dependent benefits in patients with myotonic dystrophy type 1, indicating disease-modifying potential.
- DYNE-251 demonstrated positive results in the treatment of Duchenne muscular dystrophy, but long-term safety data is still needed.
- Financially, Dyne is strong, planning a $300 million public offering to extend its cash runway.
- I maintain a "hold" on DYN stock; it fits well in a barbell investment strategy for high-risk/high-return portfolio allocation.
Moving the Muscle Market: Dyne Therapeutics' Strides in Therapy
Dyne Therapeutics' ( DYN ) stock has continued to be hot since my initial look in January. Back then, the company reported initial findings from the ACHIEVE trial, in which DYNE-101 demonstrated dose-dependent benefits in outcomes such as ASO muscle concentration and DMPK knockdown in patients with myotonic dystrophy type 1 [DM1]. In the DELIVER trial, Dyne's DYNE-251 is being compared (cross-trial) to the current standard of care, Sarepta's ( SRPT ) eteplirsen (EXONDYS 51), for the treatment of Duchenne muscular dystrophy [DMD]. That trial, too, showed positive results, but, notably, in just six patients. All in all, I recommended holding Dyne stock and monitoring its trial progress and financial health for potential buy signals....
Read the full article on Seeking Alpha
For further details see:
Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials